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Type 1 diabetes is caused by autoimmune-mediated
b cell destruction leading to insulin deficiency. The
histone deacetylase SIRT1 plays an essential role in
modulating several age-related diseases. Here we
describe a family carrying a mutation in the SIRT1
gene, in which all five affected members developed
an autoimmune disorder: four developed type 1
diabetes, and one developed ulcerative colitis.
Initially, a 26-year-old man was diagnosed with
the typical features of type 1 diabetes, including
lean body mass, autoantibodies, T cell reactivity
to b cell antigens, and a rapid dependence on
insulin. Direct and exome sequencing identified
the presence of a T-to-C exchange in exon 1 of
SIRT1, corresponding to a leucine-to-proline muta-
tion at residue 107. Expression of SIRT1-L107P in
insulin-producing cells resulted in overproduction
of nitric oxide, cytokines, and chemokines. These
observations identify a role for SIRT1 in human
autoimmunity and unveil a monogenic form of
type 1 diabetes.448 Cell Metabolism 17, 448–455, March 5, 2013 ª2013 Elsevier Inc.INTRODUCTION
Diabetes is classified into two main categories based on the
clinical presentation and pathophysiology (American Diabetes
Association, 2010). Type 1 diabetes is characterized by auto-
immune b cell destruction. Conversely, type 2 diabetes is
caused by a relative insulin deficiency in the face of insulin
resistance. Although polymorphisms in multiple genes have
been linked to overall susceptibility to diabetes, single gene
defects leading to type 1 diabetes have been identified only
in the case of AIRE and FOXP3, which are associated
with the development of complex phenotypes. Mutations in
AIRE (Finnish-German APECED Consortium, 1997; Nagamine
et al., 1997) interfere with the process of immune tolerance
to self-antigens and result in autoimmune polyendocrinopahy,
candidiasis, ectodermal dystrophy (APCED). Alternatively,
mutations in FOXP3 (Bennett et al., 2001) result in defective
development of regulatory T (Treg) cells, which leads to a
rapidly fatal condition called immunedysregulation, polyendoc-
rinopathy, enteropathy, x-linked (IPEX) syndrome. Interestingly,
recent evidence suggests that SIRT1 modulates FOXP3 and
thereby influences Treg cell development, which is essential
for the maintenance of immune homeostasis and protection
against autoimmunity (Beier et al., 2011; van Loosdregt
et al., 2010).
Figure 1. The Patients’ Family Tree and Functional Analysis of Peripheral Blood Mononuclear Cells
(A) Red symbols indicate family members who developed an autoimmune disease: type 1 diabetes (III-1, III-4, IV-1, IV-2) or colitis (IV-9). The yellow numbered
symbols denote the age of onset of the disease. Blue symbols indicate type 2 diabetes, while black symbols indicate an unclear diabetes phenotype. Black
numbered symbols identify all family members who were tested for the presence of the mutation, and the letter ‘‘M’’ identifies the ones who were positive. A slash
denotes deceased family members. Individuals IV-1 to IV 15, III-1, III-4, III-5, III-9, III-11, and III-12 are lean (body mass index <25 Kg/m2), and II-1 and III-6 have
body mass indices of 27 and >40 Kg/m2, respectively.
(B) Peripheral bloodmononuclear cells were obtained from healthy control subjects (WT) and frompatients with type 1 diabetes carrying wild-type SIRT1 (DM1) or
the L107Pmutation (MUT). GAD65515-528 peptide, whole GAD65 protein, and insulin elicited antigen-specific IFN-g production. n = 3 for each of the three groups.
All data are presented as mean ± SEM.
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Mutation of SIRT1 in a Family with Type 1 DiabetesEarly studies in budding yeast helped to identify sirtuin deace-
tylases as key enzymes that coordinate the organism’s response
to calorie intake and the regulation of life span (Banks et al.,
2008; Canto´ et al., 2009; Haigis and Guarente, 2006; Milne
et al., 2007; Westphal et al., 2007; Yoshizaki et al., 2009a).
Subsequently, the mammalian sirtuin SIRT1 has received
much attention for its role in regulating metabolism and its role
in protecting against age-related diseases (Haigis and Sinclair,
2010). Interestingly, SIRT1 is prominently expressed in b cells
and regulates insulin secretion (Bordone et al., 2006). In mice,
targeted overexpression of SIRT1 in b cells enhances insulin
secretion (Moynihan et al., 2005) and protects from apoptosis
(Tang et al., 2011). In parallel, SIRT1 also directly modulates
insulin sensitivity in peripheral tissues (Sun et al., 2007). More
recently, several reports have described a role for SIRT1 in the
regulation of cytokine production (Stein et al., 2010; Yang
et al., 2010) and maintenance of T cell tolerance (Beier et al.,
2011, 2012; van Loosdregt et al., 2010; Zhang et al., 2009a).
These results support a previous study demonstrating that
SIRT1-deficient mice exhibit sera-containing antibodies against
nuclear antigens and develop autoimmune conditions (Sequeira
et al., 2008). Furthermore, the SIRT1 activator Resveratrol hasCebeen shown to prevent and treat the spontaneous type 1 dia-
betes which normally develops in nonobese diabetic (NOD)
mice (Lee et al., 2011).
RESULTS
Description of the Patients
Type 1 diabetes was diagnosed in a 26-year-old Ashkenazi
Jewish male on the basis of hyperglycemia, a lean body mass
index of 21.5 Kg/m2, signs of b cell autoimmunity (autoantibodies
to glutamic acid decarboxylase 1,150 U/L [normal value <10],
islet-cell autoantibody-2 3.0 U/L [normal value <1.5]), and insulin
dependence (patient IV-2 in Figure 1A). Surprisingly, the
patients’ sister, father, and a paternal cousin were also diag-
nosed by their endocrinologists with type 1 diabetes at the
ages of 7, 12, and 15 years, respectively (Figure 1A). All affected
relatives were lean, displayed autoantibodies to b cells, lacked
measurable C-peptide levels, and required insulin injections.
The autoimmune nature of the disease was confirmed by as-
sessing b cell antigen-specific T cell activation by peripheral
blood mononuclear cells (Figure 1B). Interestingly, mRNA tran-
script and protein expression levels for several genes involvedll Metabolism 17, 448–455, March 5, 2013 ª2013 Elsevier Inc. 449
Figure 2. Impaired Insulin Secretion and Sensitivity in a Patient Carrying a Mutation in the SIRT1 Gene
(A) Plasma glucose and insulin levels during oral glucose tolerance tests of the index patient with a SIRT1 mutation (red lines) and a control 20-year-old non-
affected male family member (green lines).
(B) Impaired insulin stimulated glucose uptake of cultured human skeletal myotubes obtained from biopsies of the vastus lateralis muscle of the index patient with
a SIRT1 mutation (diabetes) compared to the control 20-year-old nonaffected male family member (control).
(C) The cell lysates of the myotubes were analyzed by immunoblotting with antibodies to phosphorylated and nonphosphorylated AKT, ERK, NF-kB (p65), and
AMP-K. n = 3 myotube subpopulations. All data are presented as mean ± SEM.
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Mutation of SIRT1 in a Family with Type 1 Diabetesin T cell homeostasis and regulation were decreased in Th cells.
These cells also displayed low basal and induced FOXP3 (see
Figures S1A and S1B online).
To further characterize the pathology of the index patient, an
oral glucose-tolerance test was performed 10 months after the
onset of diabetes. As expected, b cell function was severely
impaired, with a blunted insulin release following stimulation by
an oral glucose load (Figure 2A). Follow-up showed that serum
insulin and C-peptide concentrations steadily decreased over
time (50% decrease after 1 year, undetectable after 2 years).
The patient also presented some resistance to insulin, as re-
vealed by a euglycemic-hyperinsulinemic clamp study (M value
34.1 103 mM/min/Kg BW) and a muscle biopsy. The latter
yielded myoblasts displaying a reduced glucose uptake in
response to insulin along with changes in the phosphorylation
levels of the insulin-dependent proteins, Akt, ERK, and AMPK
(Figures 2B and 2C).450 Cell Metabolism 17, 448–455, March 5, 2013 ª2013 Elsevier Inc.Identification of the Mutation
The pattern of inheritance among the affected family members
was indicative of an autosomal dominant mutation (Figure 1A).
We used three different techniques in order to identify and
validate the gene(s) targeted by the inherited mutation: microsa-
tellite genotyping, targeted deep sequencing, and Sanger
sequencing of relevant candidate genes. All three techniques
converged on a single target gene, SIRT1. Whole-genome
microsatellite analysis identified a region on chromosome 10
with a significant LOD score of 4.0 between markers D10S210
and D10S537 corresponding to SIRT1 (Figure 3A and Fig-
ure S2A). Although there were segments on chromosomes 4
and 22 that yielded a LOD score of approximately 2, there
were no discernible genotype-phenotype correlations for these
regions. Direct sequencing of the SIRT1 gene revealed the pres-
ence of a T-to-C exchange in exon 1 (c.[320T > C]) present in
single copy in the DNA of the affected individuals, leading to a
Figure 3. Description of the Mutation
(A) Whole-genomemicrosatellite linkage analysis. Details of chromosome 10, for which the LOD reached significance (LOD 4.1; whole-genome significance, LOD
> 2.2). The length of the chromosome is given in centimorgans (cM). According to the UniSTS database, the region betweenmicrosatellite D10S210 and D10S537
contains the SIRT1 gene.
(B) Sanger sequence analysis of the mutation. DNA sequencing chromatograms obtained by direct sequencing of PCR products showing the presence of the
heterozygous c.[320T > C] substitution in exon 1, not present in nonaffectedmembers of the family and normal individuals (control, representative example out of
200 alleles). The roman numerals correspond to those in Figure 1A.
(C) SIRT1 gene structure and predicted protein structure.
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Mutation of SIRT1 in a Family with Type 1 DiabetesLeucine107Proline mutation in the SIRT1 protein (p. Leu107Pro,
Figures 3A and 3B). Based on the microsatellite analysis, exome
sequencing and analysis of specific areas from chromosomes 4,
10, and 22 were performed in three patients carrying the
mutation (patient III-1, III-4, and IV-2 in Figure 1A) and in three
nonaffected subjects from the same family (individuals IV-4,
IV-5, and IV-8 in Figure 1A) and confirmed that only this mutation
segregates with the phenotype of the patients (Figure S2B). The
analysis of chromosome 10 also revealed that a SNP related to
insulin activity, in KIAA1274 (Paladin), is present in the family.
However, the frequency of this SNP is high (80% homozygote
in the family and 60% in a control population), and it is equally
distributed across the whole family and independent of the
phenotype (Figure S2B). Despite its lack of correlation with
the phenotype, this SNP may have helped to precipitate the
observed type 1 diabetes, since it has been proposed to inhibit
insulin signaling (Huang et al., 2009). To rule out the possibility
of a common polymorphism in SIRT1, we searched for the pres-
ence of c.[320T > C] in 100 unrelated whites, 90 Ashkenazi Jews,
160 patients with sporadic type 1 diabetes, and 1,900 type 1 dia-Cebetes patients, with sib-pair or parent-offspring affected fami-
lies. None of these groups possessed the c.[320T > C] variant.
Moreover, this mutation has not been documented in dbSNP
(http://www.ncbi.nlm.nih.gov/snp/), in 1,000 Genomes (http://
www.1000genomes.org/), or in the Exome Variant Server
(http://evs.gs.washington.edu/EVS/). This demonstrates that
the exchange c.[320T > C] is not a common polymorphism.
However, there may exist other families with mutations in
different regions of SIRT1 that could lead to type 1 diabetes.
Of some interest, analysis of data from a genome-wide associa-
tion study (Barrett et al., 2009) for the SIRT1 locus rs12778366
showed modest evidence of association with type 1 diabetes
(p = 0.005). This SNP is in moderate LD with an eQTL signal for
SIRT1 (D0 = 1/r2 = 0.5).
Because type 1 diabetes has strong HLA associations with
linkage to certain DQ alleles, the HLA genotype was analyzed.
The results from this analysis failed to explain the high preva-
lence of the disease. Also we observed no linkage peak corre-
sponding to the HLA region on chromosome 6p21 (Table S1).
Finally, we ruled out mutations in the six MODY genes and inll Metabolism 17, 448–455, March 5, 2013 ª2013 Elsevier Inc. 451
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Mutation of SIRT1 in a Family with Type 1 Diabetesthe diabetes-associated TCF7L2, IRS2, and SOCS2 genes (data
not shown).
Nonaffected family members were healthy, with normal insulin
secretion and action, except for two individuals displaying
features typical of type 2 diabetes (advanced age at the onset
of the disease, no insulin requirement, obesity, dyslipidemia,
and hypertension; patients II-1 and III-6 in Figure 1A). All five
family members carrying the mutation were diagnosed with an
autoimmune disease, while none of the 16 noncarriers tested
were affected (Figure 1A). The segregation of the mutation in
the family was in complete agreement with the phenotypes
(maximal two-point lod score of 2.4; p < 0.0001 Fisher’s exact
test). Four members had type 1 diabetes, including a distant
member, a cousin of the patients’ father. One 18-year-old
woman carrying the mutation displayed severe ulcerative colitis
which manifested at 16 years of age (patient IV-9 in Figure 1A).
This patient required maintenance therapy with the immuno-
suppressant azathioprine and corticosteroids (repetitively).
Increased levels of anti-nuclear antibodies (titer 1:640) and atyp-
ical ANCA (titer 1:160) confirmed the autoimmune component of
her disease.
Decreased Anti-Inflammatory Activity of SIRT1-L107P
To understand how the mutation could give rise to autoimmune
defects, we tested whether any known functions of SIRT1 were
altered by the mutation. L107 lies outside of the conserved
Sirtuin enzymatic core, in a densely charged region of the
protein potentially involved in protein-protein interactions
(Autiero et al., 2009a) (Figure 3C). SIRT1-L107P showed
a mild decrease in deacetylase activity relative to the wild-
type protein (Figure S3A), and there were no changes in protein
stability, as assessed by a cycloheximide chase experiment
(data not shown). Additionally, mutation of L107P did not affect
the subcellular localization of SIRT1 (data not shown). In an
effort to identify potential protein-protein interactions affected
by the L107P substitution, we performed immunoprecipitation
experiments with the wild-type and mutant proteins. We
observed that the strongest SIRT1 interactors, identified by
mass spectrometry, were not perturbed by the mutation
(Figures S3B–S3D). Furthermore, substitution of L107P did
not affect the ability of SIRT1 to interact with eIF2a or AROS
(data not shown). Therefore, it is likely that protein-protein inter-
actions altered by the substitution are of a transient or context-
specific nature.
Based on the central role attributed to cytokines and nitric
oxide in the development of type 1 diabetes, and on the ability
of SIRT1 to suppress nitric oxide production in b cells (Lee
et al., 2009), we analyzed the effect of SIRT1-L107P on cytokine
production. Stable retroviral transduction of the b cell line MIN6
with SIRT1-L107P led to higher cytokine-induced nitric oxide
synthase expression and increased production of nitric oxide
relative to cells expressing an equal amount of wild-type SIRT1
protein (Figure 4A and Figure S4A). Moreover, SIRT1-L107P
also led to increased expression of the cytokine TNF-a and the
chemokine KC, relative to SIRT1 wild-type controls (Figure 4A).
In order to validate the importance of SIRT1 in autoimmune
destruction of b cells in vivo, we treated wild-type and SIRT1
knockout mice with multiple low doses of streptozotocin to
induce pancreatic insulitis (Like and Rossini, 1976). Interestingly,452 Cell Metabolism 17, 448–455, March 5, 2013 ª2013 Elsevier Inc.SIRT1 knockout mice displayed increased islet destruction
along with early and marked hyperglycemia (Figure 4B). Finally,
transduction of myoblasts from healthy individuals with SIRT1-
L107P resulted in insulin resistance (Figure S4B) similar to that
observed in myoblasts obtained from the index patient
(Figure 2B).
DISCUSSION
The present work describes a monogenic form of diabetes with
the typical features of type 1 diabetes (autoantibodies to b cells,
lean and young at onset of hyperglycemia, rapid disappearance
of C-peptide production and insulin dependence) together with
insulin resistance. This disease appears to be the consequence
of an autosomal-dominant mutation in the SIRT1 gene. Although
it is not typical to find insulin resistance in patients with type 1
diabetes, its prevalence may be underestimated (Wentworth
et al., 2009). The impaired b cell secretory function and insulin
resistance we observed in patients with mutated SIRT1 gene
are consistent with data from animal studies (Bordone et al.,
2006; Breitenstein et al., 2011; Moynihan et al., 2005; Sequeira
et al., 2008; Sun et al., 2007; Yang et al., 2010; Zhang et al.,
2009a), which together indicate that SIRT1 may play a pivotal
role in preventing autoimmune diseases. It is tempting to specu-
late that the disease pathology may arise as a combined conse-
quence of b cell impairment and death along with subsequent
pathological activation of the immune system. Indeed, in the
presence of insulin resistance, stress may accelerate b cell
death, which may result in the release of autoantigens together
with endogenous ‘‘danger signals’’ (alarmins) capable of
promoting pathologic self-antigen presentation (Zhang et al.,
2009b). Of particular interest is the ability of SIRT1 to suppress
TNFa expression (Yoshizaki et al., 2009b) which is partially
ablated by mutation of L107P. Importantly, both type 1 diabetes
and ulcerative colitis are strongly associated with this cytokine,
and TNF antagonism improves both conditions (Mastrandrea
et al., 2009).
Whether or not the L107P mutation is of a dominant nature
remains to be confirmed. However, both the analysis of the
family tree and the results of the in vitro studies on L107P are
suggestive of a dominant mutation. Given that the N-terminal
region of SIRT1, encompassing L107P, is thought to be involved
in binding to a broad spectrum of other proteins (Autiero et al.,
2009b; Dunker et al., 2005), it is conceivable that a point muta-
tion in this regionmay change the binding affinity toward a subset
of binding partners, resulting in an apparent dominant effect.
Together, these data indicate that SIRT1 regulates immune
function in humans and that a single amino acid substitution in
SIRT1 promotes hyperinflammation and metabolic dysfunction.
Molecules that enhance SIRT1 activity may be useful in treating
not only this disease but also other inflammatory or autoimmune
diseases.
EXPERIMENTAL PROCEDURES
Patients and Study Procedures
We conducted the study in accordance with the ethical guidelines of the
Declaration of Helsinki II; the study designwas approved by the Zurich regional
and institutional review boards. Written informed consent was obtained from
all patients.
Figure 4. Decreased Anti-Inflammatory Activity of SIRT1-L107P
(A) MIN6 cells were stably transduced with empty, wild-type (WT), or mutant SIRT1 L107P virus and stimulated with IL-1b or a combination of IL-1b and IFN-g.
iNOS mRNA expression relative to empty virus-transduced cells MIN6 cells, and NO formation following cytokine stimulation expressed as fold of unstimulated
cells. Findings were verified with five separately produced sets of sirt1 WT and L107P-overexpressing cell lines each time at least in triplicate (mean ± SD,
*p < 0.05; **p < 0.01).
(B) Wild-type and SIRT1-deficient mice were injected with five daily injections of streptozotocin (40 mg/kg). Glycemia and onset of diabetes (serum glucose
>10 mM) were monitored for 16 days. Islet histology was visualized by HE and immunostaining for insulin (brown). The proportion of surface area that stained
positive for insulin is shown. All data are presented as mean ± SEM. *p < 0.05; n = 6 for +/+ and +/, and n = 5 for /.
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Mutation of SIRT1 in a Family with Type 1 DiabetesOral glucose tolerance tests, euglycemic-hyperinsulinemic clamp studies,
and muscle biopsies were performed as described (Larsen et al., 2007).
Mutation Analysis
Genomic DNA was extracted from peripheral blood leukocytes (see the
Supplemental Information for more information).
Induction of Autoimmune Insulitis in SIRT1 Mice
Wild-type and SIRT1-deficient mice (McBurney et al., 2003) were injected with
multiple low-dose streptozotocin as previously described (Like and Rossini,
1976). Accumulation of lymphoid tissue in islets was assessed by histology.
Human Skeletal Muscle Cells
Human skeletal muscle cells were isolated from muscle biopsies by trypsin
digestion, grown to confluent myoblasts, and then differentiated into myo-
tubes as previously described (Bouzakri et al., 2003).
Plasmids and Mutagenesis
MSCV-puro containing full-length SIRT1 cDNA was subject to site-directed
mutagenesis using the QuikChange II XL Site-Directed Mutagenesis KitCe(Stratagene). The following primers were used for the mutagenesis: forward
primer, 50-AGACAATGGGCCGGGCCCGCAGGGCCCATCT-30; and reverse
primer, 50-AGATGGGCCCTGCGGGCCCGGCCCATTGTCT-30.
Retroviral Production and Infection
GP2-293 cells were cotransfected with VSVG and MSCV plasmids using
FuGENE HD transfection reagent, according to the manufacturer’s instruc-
tions. Twenty hours after transfection, the media was replaced with fresh
DMEM + 10% FBS + 1X pen/strep + 1X glutamine. Virus was harvested
between 48 and 72 hr posttransfection. Cells were targeted using filtered viral
supernatants in the presence of 5 mg/mL Polybrene (Sigma). Selection with
puromycin (0.5 mg/mL) was started 48 hr later.
Cell Culture and Protein Stability Experiments
GP2-293,293T,andNIH3T3wereall cultured inhigh-glucoseDMEMmediawith
pyruvate (GIBCO) supplemented with 10% FBS + 1X pen/strep +1X glutamine.
Cycloheximide solution (Sigma) was added to the cells to yield a final dose of
150 mg/mL and left on the cells for the indicated amount of time. Cells were
lysed for 40 min in 50 mM Tris (pH 8), 1% NP-40, 1 mM MgCl2, 10% glycerol,
and 1 mM DTT + protease inhibitor pellet (Roche).ll Metabolism 17, 448–455, March 5, 2013 ª2013 Elsevier Inc. 453
Cell Metabolism
Mutation of SIRT1 in a Family with Type 1 DiabetesImmunoprecipitation of SIRT1/SIRT1-L107P and Characterization
of Enzymatic Activity and Protein Interactors
Stable 293T cells overexpressing Flag-SIRT1 or Flag-SIRT1 L107P were lysed
and subjected to immunoprecipitation using Flag-M2 agarose (Sigma). After
washing, bound protein was eluted with 33 Flag peptide (Sigma). Enzymatic
activity was assayed using the BIOMOL SIRT1-Fluor de Lys Assay. In parallel,
protein complexes were analyzed by mass spectrometry and visualized by
western blot.
Production of MIN6 Cell Lines Expressing hSIRT1
MIN6B1 cells were kindly provided by Dr. Jun-ichi Miyazaki, University of
Osaka (Miyazaki et al., 1990). Cells were infected with pMSCV-SIRT1-Flag
(WT), with pMSCV-SIRT1-Flag (L107P), or with an empty virus as control.
Six independent sets of WT, L107P, and empty virus-harboring cell lines
were produced. Human Sirt1 expression was analyzed with the TaqMan
real-time PCR assay and by western blotting using an anti-human SIRT1 anti-
body (H-300, Santa Cruz Biotechnology), an anti-mouse SIRT1 antibody
(07-131, Millipore, and an anti-FLAG antibody (A9594, SIGMA).
To analyze the induction of iNOS, NO, KC, and TNF-a cells were treated with
1 ng/ml mouse recombinant interleukin-1b alone or in combination with
1 ng/ml interferon-g (R&D Systems, Inc., Minneapolis, MN, USA). Nitrite
concentration was determined using Griess reagent. Real-time PCR data
were normalized to 18 s, expressed relative to cells transduced with
empty virus, and analyzed with ANOVA and Bonferroni’s multiple comparison
test.
Statistical Analysis
The experimental data were analyzed with ANOVA and Bonferroni’s multiple
comparison test, and the results are expressed as means ± SEM, except
where noted.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article at http://dx.doi.
org/10.1016/j.cmet.2013.02.001.
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